We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Topical cosmetic peptide — not a dietary supplement
Argireline is a topical cosmetic ingredient, not a supplement you take internally and not a drug. It is sold legally in skincare products to affect the appearance of skin (such as wrinkles). The evidence below comes mostly from small, often industry-funded studies of topical application, so treat the effect sizes cautiously. This page is for transparency and education, not a recommendation.
What the evidence says
Most Argireline studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 2002–2017.
Based on 6 studies · 3 RCTs
Confidence
ModerateBy outcome
Argireline has an evidence score of 3/10 — emerging evidence based on 6 indexed studies. A topical cosmetic peptide — a leave-on skincare ingredient, NOT something you swallow, inject, or take as a supplement, and NOT a drug. Argireline (acetyl hexapeptide-8, also sold as acetyl hexapeptide-3) is a six-amino-acid fragment modelled on the SNAP-25 protein. It is marketed as 'topical Botox' because, in cell systems, it interferes with the SNARE complex that nerve endings use to release neurotransmitter, in theory slightly relaxing the tiny muscle contractions that create expression lines. There ARE real human topical studies — small, short, vehicle-controlled split-face wrinkle trials — and they do show modest reductions in the appearance of fine lines. But the effect sizes are small, several of the trials are industry-linked, and this is a cosmetic effect on wrinkle APPEARANCE, not a health outcome. It is generally well tolerated on skin. This entry exists to describe a cosmetic ingredient honestly, not to recommend an ingestible supplement. Representative study: PMID 23417317.
PT-141
Mostly mechanism / observationalA melanocortin-receptor (MC4R) agonist peptide for low sexual desire. Important honest framing: unlike most 'research peptides', bremelanotide is an FDA-APPROVED prescription drug — Vyleesi, approved 2019 — for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, self-injected subcutaneously on-demand. It has real phase-3 RCTs (the RECONNECT program). The catch: the approved-trial benefit was statistically significant but small (a fraction of a point on desire scales), nausea is very common, and it transiently raises blood pressure. Grey-market 'PT-141' vials sold online are NOT the approved drug and are unregulated.
Last reviewed June 2026 · evidence from 6 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Acetyl Hexapeptide-8 (Argireline)
A topical cosmetic peptide — a leave-on skincare ingredient, NOT something you swallow, inject, or take as a supplement, and NOT a drug. Argireline (acetyl hexapeptide-8, also sold as acetyl hexapeptide-3) is a six-amino-acid fragment modelled on the SNAP-25 protein. It is marketed as 'topical Botox' because, in cell systems, it interferes with the SNARE complex that nerve endings use to release neurotransmitter, in theory slightly relaxing the tiny muscle contractions that create expression lines. There ARE real human topical studies — small, short, vehicle-controlled split-face wrinkle trials — and they do show modest reductions in the appearance of fine lines. But the effect sizes are small, several of the trials are industry-linked, and this is a cosmetic effect on wrinkle APPEARANCE, not a health outcome. It is generally well tolerated on skin. This entry exists to describe a cosmetic ingredient honestly, not to recommend an ingestible supplement.
Small vehicle-controlled topical trials show modest reductions in wrinkle appearance, but effects are cosmetic-only, trials are short and often industry-linked, and skin penetration of the peptide is poor.
Argireline is the trade name for acetyl hexapeptide-8 (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, originally numbered acetyl hexapeptide-3), a synthetic six-amino-acid peptide used as a leave-on active in anti-wrinkle cosmetics.
It is a TOPICAL ingredient applied to the skin — it is not a dietary supplement, it is not ingested, and it is not injected. Its design rationale (Blanes-Mira et al., 2002) was to mimic, non-toxically, the cosmetic muscle-relaxing action of botulinum neurotoxin (BoNT).
The peptide is patterned on the N-terminal end of SNAP-25, a component of the SNARE complex that drives Ca2+-dependent vesicle fusion and neurotransmitter release at the neuromuscular junction.
By competing with SNAP-25 and interfering with SNARE-complex assembly, Argireline is proposed to dampen the small, repeated muscle contractions that, over years, etch dynamic 'expression lines' (forehead, crow's-feet, glabella) into the skin — hence the 'topical Botox' marketing.
The original work reported that a 10% oil-in-water emulsion reduced wrinkle depth by up to ~30% over 30 days in a small uncontrolled cohort, while in-vitro the peptide inhibited neurotransmitter release with potency comparable to (but efficacy far below) BoNT-A.
Since then a handful of genuinely controlled human topical trials have appeared: a randomized, placebo-controlled split-face study in Chinese subjects found significant reductions in peri-orbital wrinkle roughness over four weeks (Wang et al., 2013); a prospective randomized cosmetic-science study confirmed anti-wrinkle activity of acetyl hexapeptide-3 and reduced transepidermal water loss (Raikou et al., 2017); and an NIH double-blind placebo-controlled pilot in blepharospasm patients found topical acetyl hexapeptide-8 (framed as a SNAP-25 inhibitor) was safe and showed a non-significant trend toward extending botulinum-toxin benefit (Lungu et al., 2013).
On safety, an in-vitro cytotoxicity study found anti-proliferative effects only at concentrations 18- to 10,000-fold higher than the reference cytotoxin, supporting a wide topical safety margin. Here is the honest framing.
The evidence is real but modest: the human trials are small (tens of subjects), short (4-8 weeks), measure wrinkle APPEARANCE rather than any health endpoint, and several are linked to manufacturers of the ingredient.
A recurring scientific caveat is skin penetration — a hydrophilic hexapeptide of this size does not readily cross the stratum corneum, so real-world delivery depends heavily on formulation.
None of this is a health claim: Argireline is a lawful over-the-counter cosmetic whose documented benefit is a small, cosmetic improvement in the look of expression lines.
It is grouped here with research peptides by category convention and is sandboxed out of ingestible-supplement and goal-based recommendations; it carries a cosmetic-peptide badge and a topical-only disclaimer.
Argireline is patterned on the N-terminal end of SNAP-25 and competes with it during assembly of the SNARE complex — the protein machinery nerve terminals use for Ca2+-dependent vesicle fusion and neurotransmitter release. In cell systems it inhibits neurotransmitter release with potency similar to botulinum toxin A but far lower efficacy. This is the proposed route to relaxing expression-line muscle contraction.
By dampening the small, repeated contractions that create dynamic 'expression lines' (crow's-feet, forehead, glabella), topical Argireline is proposed to soften the appearance of fine lines over weeks of twice-daily use. This is a cosmetic, appearance-level effect demonstrated in small split-face trials — not a measured change in any health outcome.
As a hydrophilic hexapeptide, Argireline does not readily cross the stratum corneum, so the dose that actually reaches its target depends heavily on the cosmetic formulation and delivery system. This penetration limit is a recurring caveat in the literature and a reason real-world effects are modest and variable.
How Argireline works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Topical cosmetic only. Argireline is typically formulated at 5-10% in leave-on serums, creams, or gels and applied to the target area (e.g., crow's-feet, forehead) twice daily. There is no oral, injectable, or systemic dose — it is not ingested. Concentration and formulation drive how much actually penetrates the skin. This library does not provide an ingestion protocol.
Can be taken without food
| Form | Type |
|---|---|
| 🧴Leave-on topical cosmetic (serum, cream, or gel) at 5-10% | Recommended |
| 🧴Encapsulated / penetration-enhanced topical formulations | Alternative |
There is no legitimate oral or injectable form. Argireline is a cosmetic skincare active applied to the skin surface.
Minimum: 4 weeks
Optimal: 8 weeks
Cycling: Not required
Note: Applied topically to clean skin, commonly once or twice daily. As a leave-on cosmetic there is no ingestion or meal-timing consideration.
Dose-response data unavailable. The current published research for Argireline does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Every documented benefit is a modest improvement in the APPEARANCE of expression lines. Argireline is a topical cosmetic, not an ingested supplement or a drug; it does not treat any disease and is not a health outcome.
Small randomized, vehicle-controlled split-face trials report significant reductions in peri-orbital wrinkle roughness over 4-8 weeks of twice-daily use. Effect sizes are modest and some trials are industry-linked.
Topical use is associated with low irritation in the available trials, and in-vitro cytotoxicity appears only at concentrations far above cosmetic-use levels, supporting a wide topical safety margin.
The human studies enrol tens of subjects over a few weeks, measure appearance rather than health, and several are linked to ingredient manufacturers. Real-world results vary with formulation and penetration.
As with any leave-on cosmetic, mild local irritation, redness, or contact reaction is possible, particularly in sensitive skin. Patch-test before facial use.
Topical cosmetic peptides have not been formally studied in pregnancy or lactation; discuss any skincare active with a clinician. The peptide is not ingested, but evidence in these populations is absent.
Patch-test first and introduce slowly; mild irritation is the main concern with any leave-on active.
Manage expectations — the effect is a small, cosmetic improvement in the appearance of fine lines, far weaker than injectable botulinum toxin.
Layering with strong leave-on actives (retinoids, AHAs/BHAs) may increase local irritation in some people. This is a formulation/tolerance consideration, not a systemic drug interaction — Argireline is not ingested.
A small clinical pilot combined topical acetyl hexapeptide-8 with botulinum-toxin therapy without significant adverse events; any additive cosmetic effect is unproven and this is not a systemic interaction.
Tip: Patch-test before facial use; reduce frequency or discontinue if irritation occurs.
Tip: Discontinue and avoid if an allergic reaction occurs; choose a fragrance-free formulation.
The commonly studied dose of Argireline is Topical cosmetic only. Argireline is typically formulated at 5-10% in leave-on serums, creams, or gels and applied to the target area (e.g., crow's-feet, forehead) twice daily. There is no oral, injectable, or systemic dose — it is not ingested. Concentration and formulation drive how much actually penetrates the skin. This library does not provide an ingestion protocol.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Argireline — consistent daily use matters more than the time of day. Argireline is a leave-on topical cosmetic, not an ingested supplement — there is no meal-timing relationship.
Argireline is generally well-tolerated and considered safe for most healthy adults at recommended doses. The most commonly reported side effects are local skin irritation or redness, contact allergic reaction. Use caution if any of these apply to you: For topical (skin) use only — not for ingestion, not for injection; Known allergy or sensitivity to the peptide or formulation excipients; Application to broken, irritated, or compromised skin until healed.
Gonadorelin
Mostly mechanism / observationalA synthetic copy of gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pituitary to release LH and FSH. Honest appraisal: it has genuine, trial-backed roles as a diagnostic agent (the GnRH/gonadorelin stimulation test) and — delivered in pulses by an infusion pump — for inducing ovulation in hypothalamic amenorrhea and spermatogenesis in men with congenital hypogonadotropic hypogonadism. Its now-trendy use in men's TRT clinics (compounded, to 'maintain testosterone/fertility' alongside testosterone, often replacing hCG) is largely off-label and has NOT been validated in controlled trials for that purpose.